Navigation Links
Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
Date:12/30/2008

CAMBRIDGE, Mass., Dec. 30 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has received notice from The NASDAQ Stock Market stating that NASDAQ has again suspended enforcement of its minimum bid price and market value requirements for continued listing, thereby extending the Company's time in which to gain compliance. Enforcement of these rules is scheduled to resume on Monday, April 20, 2009.

The Company estimates, based on the information received, that it now has until June 15, 2009, to regain compliance with the $1.00 minimum bid price requirement. If, at any time before that date the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company should be provided written notification that it complies with the Marketplace Rule.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. On November 21, 2008, the Company announced that it had terminated most of its work force for financial reasons. Using its limited resources, the Company is developing Hemopure and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold more than 200,000 units of Oxyglobin since its launch.

Statements in this release that are not strictly historical are forward-looking statements, including any statements implying that the Company will be able to achieve the minimum bid price of $1 to avoid delisting from NASDAQ. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to pursue its business, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, delays in clinical trials, and the other factors identified under the heading "Risk Factors" in the Company's quarterly report on Form 10-Q filed on September 15, 2008, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

    Contact: Rob Skiba
             Biopure Corporation
             (617) 234-6500
             IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia
2. Biopure Sues National Institutes of Health Official
3. Agency Takes Adverse Decision to Biopures Product Registration in South Africa
4. Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
5. Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
6. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
7. Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
8. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
9. Biopure Announces Closing of $14.9 Million Financing
10. Biopures Stock Symbol Reverts to BPUR
11. Biopure Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... WASHINGTON, DC (PRWEB) , ... March 30, 2017 ... ... Truth. , On the eve of Autism Awareness Month, representatives from Organic ... Center, World Mercury Project, Focus For Health Foundation, A Voice for Choice, Moms ...
(Date:3/30/2017)... ... March 30, 2017 , ... Nutrition Education ... and Dietetics (AND), will join nonprofit Seafood Nutrition Partnership (SNP) in presenting “Eating ... designed to help nutrition educators and students inform consumers about the health benefits ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... letter to President Trump expressing their support for an independent Vaccine Safety Commission. ... scientists and one medical journalist, will hold a press conference at 9:00 ...
(Date:3/29/2017)... WI (PRWEB) , ... March 29, 2017 , ... ARI ... its exclusive provider of co-op eligible dealer websites for its network of more than ... of professional landscaping and agricultural equipment including rotary and flail mowers and cutters, rear ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... professional squash, announced it has enlisted New York City-based sports and entertainment marketing ... develop and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 Research and ... Market, Reimbursement Policy, Patients Treated at Proton Therapy Centers & Forecast" ... ... 2021 from its current market size in 2016. The Untapped Proton Therapy ... than 1 Billion USD in 2016. Proton Therapy plays ...
(Date:3/29/2017)... 2017  Zynex (OTCQB: ZYXI), an innovative medical technology company ... devices for pain management, stroke rehabilitation, cardiac monitoring and ... Company,s 2016 full-year investor webcast on Monday, April 3, 2017 at 9:00 ... Company expects to file its 2016 full year financial ... ...
(Date:3/29/2017)... March 29, 2017 According to a new market ... (Gas-Filled Detectors, Geiger Muller, Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, Badges), ... published by MarketsandMarkets, the market is expected to reach USD 1,215.4 Million ... 6.5% from 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology: